Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MrMain, that has been the question that has consumed us for quite a while now. Many feel that Amarin has to first get things rolling (in the EU primarily) before convincing a BP to consume us. Of course the other option (although probably harder to convince BP) is to market V's potential to BP now. The latter course will obviously bring much less in terms of a sale price, but the former tactic runs the risk of Amarin botching growing V enough to entice BP, and I think we can all agree that BP would be able to extract value from V much quicker. Luckily we have gained a few more years in the EU as far as protection goes.
Many here (probably not you or I) would be upset if Amarin sold itself now at a low price, but for now, I think that is a low probability as I think Denner is looking for more remuneration for his trouble. Of course if he sees the light at the end of tunnel dimming he may change his mind and want to get out with his skin intact.
If I wanted to be comical or a smart alec, I would say if you use rounding, it might be 100/0/0.
So we are back price wise to where we were two days before the ER. There was that one big up day the day before the ER where either some were speculating on a good report, or shorts were bailing ahead of the report. Of course when lightning didn't strike at the ER back down we went. So we wait.
JRoon, you very aptly describe the script history of V. Strong uptake only during an advertising and salespeople blitz. It is needed to create a blockbuster drug. Such a sad commentary on the medical community.
No advertising in Europe you have to remember. But yeah, the medical community just not falling all over themselves for V.
Are you using the dates as of reimbursements?
Hard to know. Sometimes when people speak off the cuff, they mix up tenses or omit a word. In this case it is possible he omitted the word “will” in front of “have selected”.
Don’t think I’ve ever seen (maybe just didn’t notice) prescription drugs displayed, be they brand or generic.
Would that be a Generic company like Teva or Apotex (with whom they had some relatively good relationship with for a time) or a BP like Pfizer?
Have to agree with your sentiments plus it isn’t reasonable for anyone not to have anticipated these results.
Don’t know the answer to your precise question, but Amarin is being forced to give away the farm to keep some of the b&@&t&@& insurers from completely going with the Generics. What a corrupt system we have. Best money can buy.
Direction changed on March 31, 2020. EU not developing fast or strong enough to offset what is happening here in the U.S. So many classic errors leading up to the DuDisaster.
Jasbg, sorry to hear about your experience. Now that we are older, we look back on life and realize that things can go well for decades and then all of a sudden one bad thing can lead to a terrible chain of events. After you mom’s accident it must have also been tough on her to lose her husband a year later. Life not very fair and so totally unpredictable.
Sorry to hear about your loss. Hopefully Amarin treats your progeny and mine better than it did us.
Gave some back today, but on much lower volume than yesterday, plus the overall market was a bloodbath overall.
Am I correct in saying that what you are talking about is simply data collecting, analyzing said data, and tabulating results?
Interesting about these side effects. Saw a story today about a Food Network personality that said she got really sick on the weight loss med:
https://www.foxnews.com/entertainment/food-network-star-sandra-lee-was-sick-as-sick-could-be-after-trying-weight-loss-medication
I think I am joining your logic. Only a small position here, but think I will unload on any uptick.
Thanks for the link Kiwi. A few weeks either way is no big deal anyway. Turning 73 next year, so the first RMD from tax sheltered accounts will be based on amount this coming end of the year. So if a jump in stock price doesn't occur until Jan. 1, 2025, not a bad thing. But that of course won't happen here. If study is good and they apply to FDA then stock will jump.
From a comical point of view, sometimes I feel that my diversification only seems to provide a different disaster du jour every day LOL.
North, Kiwi, as we all have interest here in CDIO and have also experienced Amarin here is another example of how insurance companies only think of today and saving money. Today CDIO released a study showing their technology identifying CVD could save the insurers 113 million. Yeah I guess some would say it is small potatoes. But the stock not going up on the news, because everyone knows insurers don't give a hoot.
Good to see today's price movement. From the link that Molee posted, it appears that the analyst covering UNCY seems to indicate data from the study coming late in the quarter, whereas you are pegging it for a month or so before. No matter, as long as it is good.
Don't know North. It would have to be some profound noticeable effect for the researchers to delve into it, as the study protocol and goals don't encompass such:
"The proposed study is a proof-of-concept, randomized, placebo-controlled, double-blind, parallel-group clinical trial assessing the efficacy of 18 months of icosapent ethyl (IPE) therapy on magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and cognitive biomarkers for AD in 150 cognitively-healthy Veterans ages 50-75 years. The overarching goal of this trial is to assess whether icosapent ethyl beneficially affects intermediate physiological measures associated with onset of AD in order to evaluate whether larger, multi-site, longer-duration Alzheimer's prevention trials are warranted to assess more definitive clinical outcomes. The proposed study aims to: 1) investigate the effects of 18 months of IPE vs. placebo on regional cerebral blood flow as measured by arterial spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers of AD pathology; and 3) evaluate the effects of 18 months of IPE vs. placebo on cognitive performance."
https://www.clinicaltrials.gov/study/NCT02719327?cond=Alzheimer%20disease&intr=Icosapent%20Ethyl&rank=1&tab=history&a=16
NORTH, I take all that BACK.. I found this on an Univ. of Wisconsin Department of Radiology website:
"In addition, data collection from this trial will allow for exploration of the impact of previous TBI and/or PTSD on response to therapy. We hypothesize that in this population, IPE will beneficially affect mechanisms central to AD pathology by: 1) increasing rCBF within the sROI; 2) reducing CSF A-beta-42; and that these neurobiological changes will be associated with 3) an increased ADCS-PACC cognitive composite score. While recognizing that the proposed trial is not addressing all potential effects of IPE, such as changes in measures of inflammation or oxidative stress, we will store neuroimages and blood and CSF samples for future analyses of other potential mechanisms."
https://radiology.wisc.edu/research-projects/brave-epa-brain-amyloid-and-vascular-effects-of-eicosapentaenoic-acid-epa-in-adults-at-risk-for-alzheimers-disease/
Absolutely.
Obviously your post was to highlight the fact that Epadel in Japan maintained market share for a long time. Much of the stuff above is of course not very applicable now since the sales force was disbanded. If Amarin can hold onto sales in the U.S. (unfortunately it is a stagnant market) while conserving cash (other than share BB) long enough to get some traction in the EU, then there may be some hope staring us at the end of a very long dark tunnel.
The following should not have been as a quote:
Sure, there may not be any interest by any big EU Pharma but imo it would not necessarily be because of reimbursements, since there are many acquisitions made well before even drug approvals, never mind reimbursements.
Kiwi, echo your sentiments about Led Zeppelin. Saw them at the Forum in Montreal in 1970. Heck I was 18 then. Where did all that time go. I used to have a grandfather who always told us about how fast time went, and we all thought he was just nuts....and old. Turns out he was right, and we were nuts. If wonder if that dynamic is because when we are young, we have very little past and are always looking to the future. When we are older, we deem ourselves to have little future left and a lot of past, that we look back on. Anyway, being in Amarin has definitely aged some of us long timers.
Thanks Capt. Sorry for the dumb questions, but here goes for anyone who knows. I know that supposedly the EU does not reimburse for Omacor, but does the UK? If not, then does Omacor have such good sales because it is dirt cheap like a generic? TIA
Well, you can also think that if the earnings were bad, they would have pre-announced them. As for pushing the stock price up, I assume that as we approach the BB, shrewd investors might buy it up thinking the BB will push the price up and they would want to get in ahead of that...... but of course this is Amarin so most likely that scenario has a slim probability.
I see that. Here is hoping for good news down the road
Especially if enough institutional investors tell him they ain’t voting for him.
Well, that didn't last too long.
Thanks for posting. The Fenofibrates would not be the only ones I would petition the FDA about. I know people will say they have no control over it, but if I sold a bottle of fish oil and told people that it will reduce CVD the FDA or FTC would come after me (if they had the resources, etc,) but in essence people who are getting Generic V or Lovaza and have been prescribed that for CVD are getting screwed because those drugs are not approved ( or even proved to be helpful) for CVD.
There is significant off label filling of people's scripts with Generic V for people who are taking it for CVD and Lovaza as well.
Have to agree with you Laurent. No other way to read the demeanor and thoughts of the 3 judges. Hopefully the trial judge is not pissed but follows their directives.
Maybe Amarin should get hackers to collate the data on V:
https://www.reuters.com/technology/cybersecurity/unitedhealth-says-hack-could-impact-data-substantial-proportion-americans-2024-04-22/
Ram, you are definitely correct about that. I believe that Kiwi though has mentioned easier things like some RWE that insurers might already have from people being on V for a number of years now.
All those statin studies were not done by one company. The FDA vigorously defended R-I at the Adcom, and although It is my opinion that there is sufficient corroborating evidence for V (Jelis, Respect?, Evaporate, etc) what is the point of a p value if studies have to be redone a myriad of times.
Your are making my point that if they were enamored with Gissi-Prevenzione, then they should over the top with R-I. Gissi was an open labelled study with no measurement of Omega-3 of participants. Many other facets too. No comparison to R-I.
Interesting that those EU countries reimbursed handsomely for Lovaza/Omacor, then stopped doing so and now with Vazkepa although not as effective at lowering trigs, nonetheless lowers trigs, doesn’t raise LDL, and have proof of reducing CVD (something Lovaza never has shown), they are so residtant to reimbursing. You would think they would be falling over themselves to cover V.
The only unfortunate thing is that they need to make an appeal to the Court of England???, and then wait for a decision and only then commence buying. They indicated almost another 2 months before they can start.